Skip to main content
. Author manuscript; available in PMC: 2018 Aug 1.
Published in final edited form as: Cancer Res. 2017 Jun 13;77(15):4158–4170. doi: 10.1158/0008-5472.CAN-16-2212

Figure 2. CD11b+ DC selectively expand at secondary sites and exhibit immunosuppressive features.

Figure 2

(A-C) Total CD11chiMHC-IIhi DC of CD45+ liver NPC from naïve (blue) and tumor-bearing (red) mice were analyzed for the expression of the indicated markers. Histograms depict expression by total liver DC (A, B) and plots show expression by CD11b- and CD11b+ subsets from tumor-bearing mice (B, bottom panel). (C) Marker expression by DC subsets from tumor-bearing mice with means ± SEM shown. *, p<0.05; **, p<0.01; ***, p<0.001 by Student's t-test.